Tag: primary HLH

March 18, 2022 Off

Gamifant Approved in China for the Treatment of Primary HLH

By Dino Mustafić

Sobi has announced that the National Medical Products Administration of China (NMPA) has approved Gamifant (emapalumab) for use in China. The indication is for treatment of adult and paediatric (newborn and older) patients with primary haemophagocytic lymphohistiocytosis (HLH) with refractory, recurrent or progressive disease or intolerance to conventional HLH therapy.